LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Cholesterol Calculation May Avoid Fasting

By LabMedica International staff writers
Posted on 23 Jan 2018
Print article
Image: New accurate cholesterol test may allow patients to pass on fasting (Photo courtesy of Johns Hopkins School of Medicine).
Image: New accurate cholesterol test may allow patients to pass on fasting (Photo courtesy of Johns Hopkins School of Medicine).
In a direct comparison study, scientists have added to evidence that a newer method of calculating low-density lipoprotein-cholesterol levels in the blood is more accurate than the older method in people who did not fast before blood was drawn.

Recent recommendations favoring non-fasting lipid assessment may impact low-density lipoprotein-cholesterol (LDL-C) estimation. The novel method of LDL-C estimation (LDL-CN) uses a flexible approach to derive patient-specific triglyceride (TG) to very low-density lipoprotein-cholesterol ratios.

Blood lipid specialists and their colleagues at Johns Hopkins School of Medicine (Baltimore, MD, USA) used a USA cross-sectional sample of 1,545,634 patients (959,153 fasting ≥10-12 hours; 586,481 non-fasting) from the second harvest of the Very Large Database of Lipids study to assess for the first time the impact of fasting status on novel LDL-C accuracy. Rapid ultracentrifugation was used to directly measure LDL cholesterol content (LDL-CD). Accuracy was defined as the percentage of LDL-CD falling within the novel method of LDL-C estimation (LDL-CN) or the classical Friedewald method (LDL-CF) category by clinical cut-point. For low estimated LDL-C (<70 mg/dL), they evaluated accuracy by TG levels. The magnitude of absolute and percent differences between LDL-CD and estimated LDL-C (LDL-CN or LDL-CF) was stratified by LDL-C and TG categories.

The scientists reported that in both fasting and non-fasting samples, accuracy was higher with the novel method across all clinical LDL-C categories (range: 87-94%) compared to Friedewald estimation (range: 71-93%). Approximately 30% of the non-fasting participants had greater than 10 mg/dL inaccurate cholesterol measurements using the Friedewald method compared with only 3% error from the actual measured value with the new method. The investigators reported that the overall accuracy of LDL calculations decreased as levels of triglycerides increased, particularly when using the Friedewald method. For example, in 6,168 non-fasting participants with high triglycerides between 200 to 399 mg/dL, the accuracy of the calculation among those in the less than 70 mg/dL LDL range was 82% with the new method versus 37% using the Friedewald method.

Seth Shay Martin, MD, MHS, an Assistant Professor of Medicine and senior author of the study, said, “Although the new LDL calculation method is a bit more complex, the beauty is that it can be performed using information that is already collected in the blood sample for the standard lipid profile and automated in the lab’s computer system to give a more accurate result. Since non-fasting samples are now accurate, it’s more convenient for patients because they can come in anytime and don’t need to return for a second appointment if they have eaten.” The study was published on January 2, 2018, in the journal Circulation.

Related Links:
Johns Hopkins School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more